Hereditary Ataxia Clinical Trial
Official title:
Pathogenic Mechanism of Spinocerebellar Ataxia Type 10 (SCA10)
| Verified date | March 2012 |
| Source | Office of Rare Diseases (ORD) |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Federal Government |
| Study type | Observational |
OBJECTIVES: I. Clinically evaluate members from families with a dominantly inherited ataxia
and collect blood, skin and muscle samples for detailed molecular studies.
II. Perform detailed clinical evaluations on patients with recessively inherited ataxias.
| Status | Completed |
| Enrollment | 18 |
| Est. completion date | March 2009 |
| Est. primary completion date | March 2009 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 3 Years and older |
| Eligibility |
Inclusion criteria: Subjects who have the diagnosis of SCA10 and their immediate relatives. Exclusion criteria: Children under 3 years of age, pregnant women, prisoners, mentally incapacitated subjects, and subjects who do not give consent. |
Observational Model: Cohort, Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| United States | University of Texas Medical Branch at Galveston | Galveston | Texas |
| Lead Sponsor | Collaborator |
|---|---|
| Office of Rare Diseases (ORD) | The University of Texas Medical Branch, Galveston |
United States,
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04750850 -
Core Stability Exercises and Hereditary Ataxia
|
N/A | |
| Active, not recruiting |
NCT06152133 -
Telerehabilitation, Core Stability Exercises and Hereditary Ataxia (TRCore-ataxia)
|
N/A | |
| Recruiting |
NCT05160883 -
Neuroimaging Changes in Hereditary Ataxia
|
||
| Recruiting |
NCT05160870 -
Genotype-phenotype Correlation and Pathogenic Mechanism in Hereditary Ataxia
|
||
| Completed |
NCT00202397 -
Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia
|
Phase 2 | |
| Recruiting |
NCT01360164 -
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia
|
Phase 1/Phase 2 |